dovitinib

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Adult Giant Cell Glioblastoma

Conditions

Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor

Trial Timeline

Dec 20, 2012 → Sep 20, 2017

NCT ID

NCT01753713

About dovitinib

dovitinib is a phase 2 stage product being developed by Novartis for Adult Giant Cell Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01753713. Target conditions include Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01888965	Phase 2	Terminated	Oct 1, 2013	Oct 1, 2014	Colorectal Cancer
NCT01732107	Phase 2	Terminated	Mar 1, 2013	Mar 6, 2017	Bladder Cancer
NCT01769547	Phase 2	Terminated	Mar 1, 2013	Jun 1, 2015	Advanced Malignant Pleural Mesothelioma
NCT01676714	Phase 2	Completed	Feb 1, 2013	Jun 1, 2016	Non-Small Cell Lung Cancer
NCT01753713	Phase 2	Completed	Dec 20, 2012	Sep 20, 2017	Adult Giant Cell Glioblastoma
NCT01266070	Phase 2	Terminated	Nov 1, 2012	Dec 1, 2015	Von Hippel-Lindau Syndrome
NCT01678105	Phase 2	Completed	Nov 1, 2012	Sep 1, 2015	Recurrent Adenoid Cystic Carcinoma of the Salivary Glands
NCT01719549	Phase 2	Completed	Sep 1, 2012	Nov 1, 2016	Gastric Cancer
NCT01791387	Phase 2	UNKNOWN	Mar 1, 2012	Jun 1, 2015	Clear Cell Renal Cell Carcinoma
NCT01262027	Phase 2	Completed	Jan 27, 2012	Nov 25, 2015	Breast Cancer
NCT01443481	Phase 1	Completed	Nov 1, 2011	Oct 1, 2014	Solid Tumors

Competing Products

20 competing products in Adult Giant Cell Glioblastoma

See all competitors

Product	Company	Stage	Hype Score
BBP-398 + sotorasib	BridgeBio Pharma	Phase 1	30
Daridorexant + Placebo	Idorsia	Phase 1	28
SON-1010 (IL12-FHAB)	Sonnet BioTherapeutics	Phase 1	28
Somatropin	Eli Lilly	Phase 3	77
agenT-797	MiNK Therapeutics	Phase 1	25
Pegilodecakin	Eli Lilly	Phase 1	33
eFT226 + Sotorasib + Fulvestrant + Abemaciclib + Trastuzumab	eFFECTOR Therapeutics	Phase 1/2	33
Lazertinib(G001) + Lazertinib(G002)	Yuhan	Phase 1	33
Patritumab deruxtecan	Daiichi Sankyo	Phase 2	52
DJ-927 + capecitabine	Daiichi Sankyo	Phase 1	33
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	52
Roxadustat	Astellas Pharma	Phase 1	33
ASP3325 + Placebo	Astellas Pharma	Phase 1	33
TRK-100STP	Astellas Pharma	Phase 1	33
Ensitrelvir	Shionogi	Phase 1	33
E6130 + Placebo	Eisai	Phase 1	33
E7389 + E7389 + E7389	Eisai	Phase 1	33
Eribulin Mesylate	Eisai	Phase 1	33
E2022 + E2022 + E2022 + E2022 + E2022	Eisai	Phase 1	33
Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride	Eisai	Phase 1	33

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved